Octanoic acid in alcohol-responsive essential tremor: A randomized controlled study

Neurology

Volumn 80, Issue 10, 2013, Pages 933-940

  Haubenberger, Dietrich ^a,b   McCrossin, Gayle ^a   Lungu, Codrin ^a   Considine, Elaine ^a   Toro, Camilo ^c   Nahab, Fatta B ^d   Auh, Sungyoung ^a   Buchwald, Peter ^d   Grimes, George J ^e   Starling, Judith ^e   Potti, Gopal ^e   Scheider, Linda ^a   Kalowitz, Daniel ^a   Bowen, Daniel ^e   Carnie, Andrea ^a   Hallett, Mark ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Pharmaceutical Development Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCTANOIC ACID; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL TREMOR; FATIGUE; FEMALE; HAND TREMOR; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE PAIN; LOW DRUG DOSE; MALE; MUSCLE CRAMP; NAUSEA; ODOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TASTE; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ALCOHOLIC BEVERAGES; CAPRYLATES; DOUBLE-BLIND METHOD; ESSENTIAL TREMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME;

EID: 84876220097     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182840c4f     Document Type: Article

References (18)

1. Deuschl G, Wenzelburger R, Löffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction: clinical and kinematic analysis of intention tremor. Brain 2000;123(pt 8): 1568-1580.
2. Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol 1994;35:717-723.
3. Lou JS, Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology 1991;41:234-238.
4. Hague S, Rogaeva E, Hernandez D, et al. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 2003;54:271-274.
5. Bushara KO, Goldstein SR, Grimes GJ, Burstein AH, Hallett M. Pilot trial of 1-octanol in essential tremor. Neurology 2004;62:122-124.
6. Shill HA, Bushara KO, Mari Z, Reich M, Hallett M. Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. Neurology 2004;62:2320-2322.
7. Nahab FB, Wittevrongel L, Ippolito D, et al. An openlabel, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. Neurotherapeutics 2011;8: 753-762.
8. Nahab FB, Handforth A, Brown T, et al. Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor. Neurotherapeutics 2012;9:635-638.
9. Sills MA, Forsythe WI, Haidukewych D, MacDonald A, Robinson M. The medium chain triglyceride diet and intractable epilepsy. Arch Dis Child 1986;61:1168-1172.
10. Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol 2011;10: 148-161.
11. Louis ED, Rios E, Henchcliffe C. How are we doing with the treatment of essential tremor (ET)? Persistence of patients with ET on medication: data from 528 patients in three settings. Eur J Neurol 2010;17:882-884.
12. Louis ED, Barnes L, Albert SM, et al. Correlates of functional disability in essential tremor. Mov Disord 2001;16:914-920.
13. Deuschl G, Bain P, Brin M. Consensus statement of the movement disorder society on tremor. Ad Hoc Scientific Committee. Mov Disord 1998;3(13 suppl):2-23.
14. Elble R, Lewitt PA, Lyons K, et al. Reliability of the essential tremor rating assessment scale (TETRAS). Mov Disord 2012;27(suppl 1):S409.
15. Haubenberger D, Kalowitz D, Nahab FB, et al. Validation of digital spiral analysis as outcome parameter for clinical trials in essential tremor. Mov Disord 2011;26: 2073-2080.
16. Oldendorf WH. Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids. Am J Physiol 1973;224:1450-1453.
17. Mostile G, Jankovic J. Alcohol in essential tremor and other movement disorders. Mov Disord 2010;25:2274-2284.
18. Sills MA, Forsythe WI, Haidukewych D. Role of octanoic and decanoic acids in the control of seizures. Arch Dis Child 1986;61:1173-1177.